



Jagsonpal Pharmaceuticals Ltd

Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar,
Sector-18, Gurugram -122015, Haryana (India)

Ph.: +91 124 4406710; **E-mail:** info@jagsonpal.com; **Website:** www.jagsonpal.com

CIN. : L74899DL1978PLC009181



April 27, 2026

The Department of Corporate Services- Listing BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789	The Department of Corporate Services- Listing National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM
---	--

Subject: Press Release on approval of Buy- Back of Equity shares of the Company

Dear Sir/ Madam,

Please find enclosed herewith a copy of the Press Release regarding the approval of Buy- Back of Equity shares of the Company.

We request you to take the above on record.

Thanking you

For **Jagsonpal Pharmaceuticals Limited**

Pratham Rawal
Company Secretary & Compliance Officer

Encl.: A/a



Jagsonpal Pharmaceuticals Limited secures Shareholders' Approval for Buyback

Gurugram, India | April 27, 2026 – Jagsonpal Pharmaceuticals Ltd. has announced the shareholders approval for the proposal to buy-back equity shares of the Company. This marks a significant milestone in the Company's sustained efforts to enhance shareholder value.

Reinforcing its commitment to delivering long-term value to shareholders through optimised capital structure, the Board had on March 12, 2026 proposed buyback of upto 16 lakh equity shares at Rs. 250/- per equity share aggregating an amount of upto Rs. 40 Crores. The proposal was subject to shareholders approval, results of which were announced today.

The endorsement by shareholders for the proposed buyback reflects continuing investor confidence in Jagsonpal's strategic direction, financial discipline, and long-term growth prospects. The buyback is aimed at optimizing capital allocation, improving earnings per share (EPS), and delivering meaningful returns to shareholders.

The buyback is aligned with the Company's broader strategy of balancing growth investments with shareholder returns.

The way forward on the proposed buyback, including timelines and record date, will be communicated in due course in accordance with applicable regulations.

ABOUT JAGSONPAL PHARMACEUTICALS LIMITED

Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company with a proven track record of over four decades in the Indian pharmaceutical market.

The Company has a robust portfolio of drugs focusing on Gynaecology, Orthopaedics, Dermatology and Child-care segments. Over the years, the Company has successfully built multiple brands that today hold market-leading positions in their respective segments. It has created a strong niche for itself with 20+ brands amongst Top 5 brands in the molecule category, extensive pan-India presence and an experienced sales team of over 1000 professionals.

The company is listed on the National Stock Exchange Limited (JAGSNPHARM) and Bombay Stock Exchange (Scrip code: 507789) and is headquartered in Delhi.

For more information, please visit: www.jagsonpal.com

Company contact	Investor Relations Team
<p>Email: cs@jagsonpal.com, Tel: +91 124 4406710</p> <p>Jagsonpal Pharmaceuticals Limited CIN: L74899DL1978PLC009181 Registered Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 Corporate Office: Nimai Tower, 3rd floor, Udyog Vihar, Gurugram, Haryana – 122015</p>	<p>Soumya Chhajed Email- soumya@goindiaadvisors.com Mobile: +91-8619707750</p>

JAGSONPAL